Similarly, another CaCC inhibitor, diethylstilbestrol (DES), also inhibits ANO1 and ANO2, reduces EGFR activation, and decreases non-small cell lung cancer (NSCLC) cell migration [171]. Here, EGFR is linked to non-small cell lung carcinoma.